

Study Phase Plan: MicroFlow^{BASIC} Micronucleus Analysis Kit (M52MFv16)

Mouse Bone Marrow

An original signed Study Phase Plan document and Sample Submission Form are required for each study.

A. Contact Information

Test Facility Name and Address:

Test Facility Study Director:

Name _____
Phone _____
Fax _____
Email _____

Test Site Name and Address:

Litron Laboratories
3500 Winton Place, Suite 1B
Rochester, New York 14623
phone: 585-442-0930
fax: 585-442-0934
info@litronlabs.com
www.litronlabs.com

Test Facility Lead QA Auditor:

Name _____
Phone _____
Fax _____
Email _____

B. Study Information

Study ID: _____

For analysis in compliance with GLP regulations, initial here. Provide the agency name that the data will be submitted to: _____. Also, indicate which GLP regulations should be followed (FDA and/or OECD): _____. A copy of your protocol is required prior to sample analysis. For FDA GLP analyses, label samples with Sample ID, Study ID, Date Collected, Source (i.e., mouse) and Type (i.e., bone marrow). For OECD GLP, label samples with Unique ID and Sample ID.

For Non-GLP analysis, initial here if a final report is requested in addition to the electronic data file.

Initial here for statistical analysis of data. Additional charges apply. Contact Litron for details.

All study phase specific records will be sent to your test facility after study phase completion, otherwise initial here to have records retained at Litron (see Section 8).

C. If applicable, please indicate any requested modifications to this Study Phase Plan:

D. Study Phase Plan Approval

Study Director Signature: _____ **Date:** _____

For Litron use only	
Principal Investigator _____	GLP Number: _____
Principal Investigator's Signature	Date

1. Objective

This MicroFlow® Study Phase Plan describes procedures for analyzing test facility-prepared mouse bone marrow samples for the presence of micronuclei (MN) using the MicroFlow procedure. Micronuclei will be analyzed in the High CD71-positive immature erythrocyte (also called polychromatic erythrocyte or PCE) population to provide an indication of genotoxicity. The frequency of High CD71-positive PCEs (% PCE) among total red blood cells (RBCs) is also measured to provide an indication of bone marrow toxicity. The analysis can be performed under US Food and Drug Administration (FDA) and/or Organisation for Economic Co-Operation and Development (OECD) Good Laboratory Practice (GLP) guidelines (see Section B).

2. Introduction

The *in vivo* Micronucleus Assay is capable of detecting clastogenic (chromosome-breaking) and aneugenic (whole chromosome loss) activity. When cell division occurs, the chromosome fragments or whole chromosomes that are not included in the main nucleus become a micronucleus. Erythrocytes expel their main nucleus before entering the bloodstream, making them ideal for measuring fragmented DNA. Flow cytometry is used for this analysis, as it provides a high-speed method for objective scoring of these rare events. Stained cells fluoresce as they pass through a focused laser beam, and the collected data is then sent to a computer for analysis. Micronuclei occur spontaneously, but clastogens and aneugens cause an increase in the number of MN relative to the background (spontaneous) level.

3. Proposed Study Dates

The experimental start and end dates will be documented in the MicroFlow report.

4. Experimental Procedures (performed at Test Facility)

The test facility is responsible for following the procedures detailed in the Litron-provided manual. Substitutions of kit components or deviations from the procedures described in the manual are not recommended. Modifications not previously approved by Litron may result in samples that are incompatible with flow cytometric analysis.

5. Flow Cytometric Analysis (performed at Test Site)

- **Sample Receipt**

Upon receipt at Litron, the fixed samples will be stored in a freezer (-85 °C ± 5 °C) until preparation for analysis.

- **Sample Preparation**

The fixed samples will be washed with a cold, balanced salt solution (will include Fetal Bovine Serum if samples are stored in Long Term Storage Solution) and isolated by centrifugation. The resulting cell pellets will be stored at 2 °C to 10 °C or on ice until staining.

- **Staining for Identification of Cell Populations**

Samples will be incubated with RNase (to degrade RNA), a fluorescently labeled antibody to the transferrin receptor (anti-CD71-FITC) to stain PCEs, and a fluorescently labeled antibody to label platelets (anti-CD61-PE). After incubation, cells will be stored at 2 °C to 10 °C or on ice until analysis. A propidium iodide solution will be added to each sample before flow cytometric analysis to stain DNA.

- **Flow Cytometer Calibration**

Methanol-fixed blood from mice infected with *Plasmodium berghei* will be used to configure the flow cytometer before analysis. Whereas MN are relatively rare and exhibit a heterogeneous DNA content, parasitized cells are prevalent and have a homogenous DNA content. These characteristics make them ideal for calibrating the flow cytometer for the micronucleus scoring application.

- **Analysis of Samples**

Samples will be analyzed by flow cytometry. The stained cells are moved past a laser set to provide 488 nm excitation. The fluorescence emitted by each cell is collected by photomultiplier tubes. Using the previously described staining procedure, the propidium iodide-stained DNA of the micronuclei emit a red fluorescence, the anti-CD71-FITC antibody emits a high green fluorescent signal, and platelets are excluded based on anti-CD61-PE fluorescence.

6. Data Provided

When possible, twenty thousand PCEs are analyzed per sample. In the event of bone marrow toxicity, the number analyzed may be reduced according to Litron's SOPs. The number of normochromatic erythrocytes (NCEs), MN-NCEs, PCEs and MN-PCEs are provided for each sample. The frequency of MN-PCEs will be calculated as an indication of genotoxic potential. The % PCE will be determined to provide an indication of bone marrow toxicity. Averages and standard deviations, per group and sex, will be provided (if known).

7. Evaluation and Interpretation of Results

No statistical analyses will be performed on the data, other than the calculations indicated above, and the test facility will be responsible for the evaluation and interpretation of results, unless the appropriate box in section B is initiated. If statistical analyses are requested, Litron's SOP for statistical evaluation will be followed.

8. Records Maintained

If requested in Section B, the original study phase plan, original MicroFlow report, and study-specific records (copies, if applicable) will be transferred to the test facility at the completion of the study phase. Litron will maintain copies of the report, protocol, study phase plan, and other study-specific records for two years following completion of the study. After the retention period, Litron will contact the sponsor and study-specific records will either be discarded or sent to the sponsor-requested facility.

9. References

- Asanami S, Shimono K, Sawamoto O, Kurisu K and Uejima M (1995) *Mutation Research* 347, 73-78.
- Asano N, Torous DK, Tometsko CR, Dertinger SD, Morita T, and Hayashi M (2006) *Mutagenesis* 21(1), 15-20
- Wakata A, Miyamae Y, Sato S, Suzuki T, Morita T, Asano N, Awogi T, Kondo K and Hayashi M (1998) *Environmental Molecular Mutagenesis* 32, 84-100.
- Dertinger SD, Torous DK and Tometsko CR (1996) *Mutation Research* 371, 283-292.
- Dertinger SD, Torous DK, Hall NE, Tometsko CR and Gasiewicz TA (2000) *Mutation Research* 464, 195-200.
- Dertinger SD, Camphausen K, Macgregor JT, Bishop ME, Torous DK, Avlasevich S, Cairns S, Tometsko CR, Menard C, Muanza T, Chen Y, Miller RK, Cederbrant K, Sandelin K, Pontén I and Bolcsfoldi G (2004) *Environmental Molecular Mutagenesis* 44, 427-435.
- Dertinger SD, Bishop ME, McNamee JP, Hayashi M, Suzuki T, Asano N, Nakajima M, Saito J, Moore M, Torous DK and MacGregor JT (2006) *Toxicological Sciences* 94, 83-91.
- Dertinger SD, Tsai Y, Nowak I, Hyrien O, Sun H, Bemis JC, Torous DK, Keng P, Palis J and Chen Y (2007) *Mutation Research* 634, 119-125.
- Dertinger SD, Bemis JC, Phonethepswath S, Tsai Y, Nowak I, Hyrien O, Palis J and Chen Y (2009) *Mutation Research* 675(1-2), 77-80.
- Goff JP, Shields DS, Seki M, Choi S, Epperly MW, Dixon T, Wang H, Bakkenist CJ, Dertinger SD, Torous DK, Wittschieben J, Wood RD and Greenberger JS (2009) *Radiation Research* 172(2),
- Hayashi M, Sofuni T and Ishidate M (1983) *Mutation Research* 121, 241-247.
- Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Dertinger SD, Abramsson-Zetterberg L, Krishna G, Morita T, Russo A, Asano N, Suzuki H, Ohyama W and Gibson D (2007) *Mutation Research* 627, 10-30.
- Heddle JA (1973) *Mutation Research* 18, 187-190.
- Heddle JA, Hite M, Kirkhart B, Mavournin K, MacGregor JT, Newell GW and Salamone MF (1983) *Mutation Research* 123, 61-118.
- Holden H, Majeska J and Studwell D (1997) *Mutation Research* 391, 87-89.
- Kissling GE, Dertinger SD, Hayashi M and MacGregor JT (2007) *Mutation Research* 634, 235-240.
- MacGregor JT, Wehr CM and Gould DH, (1980) *Environmental Mutagenesis* 2, 509-514.
- MacGregor JT, Bishop ME, McNamee JP, Hayashi M, Asano N, Wakata A, Nakajima M, Saito J, Aidoo A, Moore M and Dertinger SD (2006) *Toxicological Sciences* 94, 94-107.
- Patent numbers: 2,529,802, 5,858,667, 6,100,038, 7,425,421, 7,867,447, 8,076,095, 8,586,321, and patents pending.
- Romagna, F and Staniforth, CD (1989) *Mutation Research* 213, 91-104.
- Salamone M, Heddle J, Stuart E and Katz M (1980) *Mutation Research* 74, 347-356.
- Salamone MF and Heddle JA (1983) In: F.J. de Serres, ed. *Chemical Mutagens: Principles and Methods for their Detection*, Vol 8. New York: Plenum, 1983; 111-149.
- Schmid W (1975) *Mutation Research* 31, 9-15.
- Serke S and Huhn D (1992) *British Journal of Haematology* 81, 432-439.
- Tometsko AM, Torous DK and Dertinger SD (1993) *Mutation Research* 292, 129-135.
- Tometsko AM, Dertinger SD and Torous DK (1993) *Mutation Research* 292, 137-143.
- Tometsko AM, Torous DK and Dertinger SD (1993) *Mutation Research* 292, 145-153.
- Tometsko AM, Dertinger SD and Torous DK (1995) *Mutation Research* 334, 9-18.
- Torous DK, Hall NE, Dertinger SD, Diehl MS, Illi-Love AH, Cederbrant K, Sandelin K, Bolcsfoldi B, Ferguson LR, Pearson A, Majeska JB, Tarca JP, Hewish DR, Doughty L, Fenech M, Weaver JL, Broud DD, Gatehouse DG, Hynes GM, Kwanyuen P, McLean J, McNamee JP, Parenteau M, Van Hoof V, Vanparys P, Lenarczyk M, Siennicka J, Litwinska B, Slowikowska MG, Harbach PR, Johnson CW, Zhao S, Aaron CS, Lynch AM, Marshall IC, Rodgers B and Tometsko CR (2001) *Environmental and Molecular Mutagenesis* 38, 59-68.
- Torous DK, Hall NE, Murante FG, Gleason SE, Tometsko CR and Dertinger SD (2003) *Toxicological Sciences* 74, 309-314.
- Torous DK, Hall NE, Illi-Love AH, Diehl MD, Cederbrant K, Sandelin K, Pontén I, Bolcsfoldi G, Ferguson LR, Pearson A, Majeska JB, Tarca JP, Hynes GM, Lynch AM, McNamee JP, Bellier PV, Parenteau M, Blakey D, Bayley J, van der Leede BM, Vanparys P, Harbach PR, Zhao S, Filipunas AL, Johnson CW, Tometsko CR and Dertinger SD (2005) *Environmental Molecular Mutagenesis* 45, 44-55.
- Torous D, Asano N, Tometsko C, Sugunan S, Dertinger S, Morita T and Hayashi M (2006) *Mutagenesis* 21, 11-13
- Torous DK, Dertinger SD, Hall NE and Tometsko CR (2000) *Mutation Research* 465, 91-99.
- Witt KL, Livanos E, Kissling GE, Torous DK, Caspary W, Tice RR, and Recio L (2007) *Mutation Research* 649, 101-113.
- Section 4 of the OECD Guidelines for the Testing of Chemicals: Mammalian Erythrocyte Micronucleus Test, Guideline 474 (Adopted 26th September 2014).
- Where applicable, GLP regulations for non-clinical laboratory studies as developed by the FDA (21 CFR 58). Please note that the computerized systems utilized for data acquisition, data analysis and report generation have undergone an internal validation guided by FDA GLP regulations. Litron is working towards 21 CFR part 11 compliance.
- Where applicable, Principles of GLP by OECD [C(97)186/FINAL].
- Where applicable, ISO 10993-3: Biological evaluation of medical devices – Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicology (2003-10-15).
- Where applicable, ICH Harmonised Tripartite Guideline: Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use, S2(R1), current Step 4 version dated 9 November 2011.

10. Effective Date: August 01, 2021